



**Department of Vermont Health Access
Pharmacy Benefits Management Program
*DUR Board Meeting Agenda***

June 26, 2012 6:30 – 9:00 p.m.

- 1. Executive Session** **6:30 - 7:00**
 - Discussion on Medicaid OBRA'90/Supplemental Rebates and Agreements (as provided by 33 VSA § 1998(f)(2))

- 2. Introductions and Approval of DUR Board Minutes** **7:00 - 7:05**
(Public Comment Prior to Board Action)

- 3. Election of DUR Board Chair** **7:05-7:15**
(call for nominations and election)

- 4. DVHA Pharmacy Administration Updates** **7:15 - 7:25**
 - Updates
 - Prescribed Product Disclosures: Report for Fiscal Year 2011

- 5. Medical Director Update** **7:25 - 7:30**
 - Clinical Programs Update
 - Prescriber Comments

- 6. Follow-up Items from Previous Meetings** **7:30 - 7:45**
 - Xifaxan[®] in Hepatic Encephalopathy
 - Atypical Antipsychotics – Pediatric Use
 - Letter to Prescribers regarding Days' Supply and Early Refill
 - Pharmacy Newsletter

- 7. RetroDUR/DUR** **7:45 – 7:45**
 - None

- 8. Clinical Update: Drug Reviews** **7:45 – 8:00**
(Public comment prior to Board action)
 - Abbreviated New Drug Reviews**
 - Duexis[®] (famotidine/ibuprofen) Oral Tablet
 - Opana[®] ER (oxymorphone ER) (Crush Resistant Formulation)

 - Full New Drug Reviews**
 - Kalydeco[®] (ivacaftor) Oral Tablet

- 9. Therapeutic Drug Classes – Periodic Review** **8:00 – 8:20**
(Public comment prior to Board action)
Class review documents available on DVHA web site 6/26/2012 @ 12 Noon
- Anticoagulants
 - Injectable
 - Oral
 - DPP-4 Inhibitors and Combinations (includes review of Janumet XR[®], Jentadueto[®])
 - Hereditary Angioedema Agents
- 10. New Managed Therapeutic Drug Classes** **8:20 – 8:20**
(Public comment prior to Board action)
- None
- 11. Review of Newly-Developed/Revised Clinical Coverage Criteria and/or Preferred Products** **8:20 – 8:50**
(Public comment prior to Board action)
- Anti-hyperkinesia and Anti-Narcolepsy: ADHD (quantity limits)
 - Multiple Sclerosis Medications (new information Gilenya[®] and Tysabri[®])
 - Nutritional Products
- 12. General Announcements** **8:50– 9:00**
Selected FDA Safety Alerts
- Aliskiren-Market withdrawal of Valtorna[®]
 - Tysabri[®] - Drug Safety Communication – Update of Risk Factors for PML
- 13. Adjourn** **9:00**